Classen Immunotherapies' Peer Reviewed Data Suggests the Measles/Mumps/Rubella Vaccine Protects Against COVID-19, Additional Studies in Progress

2020-05-19 14:16:41 - BALTIMORE - (PR Distribution™)

Classen Immunotherapies Inc. has just published in the peer reviewed journal Diabetes & its Complications  evidence that the measles/mumps/rubella vaccine  may provide protection against infections with COVID-19. Non peer reviewed data from several other groups support this finding. These findings are not meant to be a clinical recommendation.  

US military has stated that the COVID-19 pandemic may be an bioweapon attack. Several respected scientist have claimed that the  genome of COVID-19 actually supports that the virus is man made. In the current publication the author explores the possibility that the COVID-19 pandemic may be a bioweapon attack. “The first step to resolve the pandemic must be to determine if the COVID-19 pandemic is a biological weapons attack”   Classen states.  

To learn more about the research of immunologist J. Bart Classen, MD  see the website http://www.vaccines.net 

For further information contact  [email protected]

Media Contacts:


Full Name
. Bart Classen, MD
Company
Classen Immunotherapies, Inc
Phone Number
Website
Email
View Results in Google